Arterial Hypertension and Interleukins: Potential Therapeutic Target or Future Diagnostic Marker?
Hypertension as a multifactorial pathology is one of the most important cardiovascular risk factors, affecting up to 30-40% of the general population. Complex immune responses are involved in the inflammatory mechanism of hypertension, with evidence pointing to increased inflammatory mediators even...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | International Journal of Hypertension |
| Online Access: | http://dx.doi.org/10.1155/2019/3159283 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832567096530173952 |
|---|---|
| author | Daniela Maria Tanase Evelina Maria Gosav Smaranda Radu Anca Ouatu Ciprian Rezus Manuela Ciocoiu Claudia Florida Costea Mariana Floria |
| author_facet | Daniela Maria Tanase Evelina Maria Gosav Smaranda Radu Anca Ouatu Ciprian Rezus Manuela Ciocoiu Claudia Florida Costea Mariana Floria |
| author_sort | Daniela Maria Tanase |
| collection | DOAJ |
| description | Hypertension as a multifactorial pathology is one of the most important cardiovascular risk factors, affecting up to 30-40% of the general population. Complex immune responses are involved in the inflammatory mechanism of hypertension, with evidence pointing to increased inflammatory mediators even in prehypertensive patients. Increased vascular permeability, thrombogenesis, and fibrosis, effects that are associated with sustained hypertension, could be attributed to chronic inflammation. Chronic inflammation triggers endothelial dysfunction via increased production of ROS through proinflammatory cytokines. Increased serum level of proinflammatory cytokines such as IL-1β, IL-6, IL-8, IL-17, IL-23, TGFβ, and TNFα in hypertensive patients has been associated with either increased blood pressure values and/or end-organ damage. Moreover, some cytokines (i.e., IL-6) seem to determine a hypertensive response to angiotensin II, regardless of blood pressure values. Understanding hypertension as an inflammatory-based pathology gives way to new therapeutic targets. As such, conventional cardiovascular drugs (statins, calcium channels blockers, and ACEIs/ARBs) have shown additional anti-inflammatory effects that could be linked to their blood pressure lowering properties. Moreover, anti-inflammatory drugs (mycophenolate mofetil) have been shown to decrease blood pressure in hypertensive patients or prevent its development in normotensive individuals. Further research is needed to evaluate whether drugs targeting hypertensive-linked proinflammatory cytokines, such as monoclonal antibodies, could become a new therapeutic option in treating arterial hypertension. |
| format | Article |
| id | doaj-art-525a16978e064783ad735815306be465 |
| institution | Kabale University |
| issn | 2090-0384 2090-0392 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Hypertension |
| spelling | doaj-art-525a16978e064783ad735815306be4652025-02-03T01:02:23ZengWileyInternational Journal of Hypertension2090-03842090-03922019-01-01201910.1155/2019/31592833159283Arterial Hypertension and Interleukins: Potential Therapeutic Target or Future Diagnostic Marker?Daniela Maria Tanase0Evelina Maria Gosav1Smaranda Radu2Anca Ouatu3Ciprian Rezus4Manuela Ciocoiu5Claudia Florida Costea6Mariana Floria7Department of Internal Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, 700111, RomaniaDepartment of Internal Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, 700111, RomaniaDepartment of Cardiology, “Prof. Dr. George I.M. Georgescu” Institute of Cardiovascular Diseases, Iasi, 700503, RomaniaDepartment of Internal Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, 700111, RomaniaDepartment of Internal Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, 700111, RomaniaDepartment of Pathophysiology, Faculty of Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, 700111, RomaniaDepartment of Ophthalmology, Faculty of Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, 700111, RomaniaDepartment of Internal Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, 700111, RomaniaHypertension as a multifactorial pathology is one of the most important cardiovascular risk factors, affecting up to 30-40% of the general population. Complex immune responses are involved in the inflammatory mechanism of hypertension, with evidence pointing to increased inflammatory mediators even in prehypertensive patients. Increased vascular permeability, thrombogenesis, and fibrosis, effects that are associated with sustained hypertension, could be attributed to chronic inflammation. Chronic inflammation triggers endothelial dysfunction via increased production of ROS through proinflammatory cytokines. Increased serum level of proinflammatory cytokines such as IL-1β, IL-6, IL-8, IL-17, IL-23, TGFβ, and TNFα in hypertensive patients has been associated with either increased blood pressure values and/or end-organ damage. Moreover, some cytokines (i.e., IL-6) seem to determine a hypertensive response to angiotensin II, regardless of blood pressure values. Understanding hypertension as an inflammatory-based pathology gives way to new therapeutic targets. As such, conventional cardiovascular drugs (statins, calcium channels blockers, and ACEIs/ARBs) have shown additional anti-inflammatory effects that could be linked to their blood pressure lowering properties. Moreover, anti-inflammatory drugs (mycophenolate mofetil) have been shown to decrease blood pressure in hypertensive patients or prevent its development in normotensive individuals. Further research is needed to evaluate whether drugs targeting hypertensive-linked proinflammatory cytokines, such as monoclonal antibodies, could become a new therapeutic option in treating arterial hypertension.http://dx.doi.org/10.1155/2019/3159283 |
| spellingShingle | Daniela Maria Tanase Evelina Maria Gosav Smaranda Radu Anca Ouatu Ciprian Rezus Manuela Ciocoiu Claudia Florida Costea Mariana Floria Arterial Hypertension and Interleukins: Potential Therapeutic Target or Future Diagnostic Marker? International Journal of Hypertension |
| title | Arterial Hypertension and Interleukins: Potential Therapeutic Target or Future Diagnostic Marker? |
| title_full | Arterial Hypertension and Interleukins: Potential Therapeutic Target or Future Diagnostic Marker? |
| title_fullStr | Arterial Hypertension and Interleukins: Potential Therapeutic Target or Future Diagnostic Marker? |
| title_full_unstemmed | Arterial Hypertension and Interleukins: Potential Therapeutic Target or Future Diagnostic Marker? |
| title_short | Arterial Hypertension and Interleukins: Potential Therapeutic Target or Future Diagnostic Marker? |
| title_sort | arterial hypertension and interleukins potential therapeutic target or future diagnostic marker |
| url | http://dx.doi.org/10.1155/2019/3159283 |
| work_keys_str_mv | AT danielamariatanase arterialhypertensionandinterleukinspotentialtherapeutictargetorfuturediagnosticmarker AT evelinamariagosav arterialhypertensionandinterleukinspotentialtherapeutictargetorfuturediagnosticmarker AT smarandaradu arterialhypertensionandinterleukinspotentialtherapeutictargetorfuturediagnosticmarker AT ancaouatu arterialhypertensionandinterleukinspotentialtherapeutictargetorfuturediagnosticmarker AT ciprianrezus arterialhypertensionandinterleukinspotentialtherapeutictargetorfuturediagnosticmarker AT manuelaciocoiu arterialhypertensionandinterleukinspotentialtherapeutictargetorfuturediagnosticmarker AT claudiafloridacostea arterialhypertensionandinterleukinspotentialtherapeutictargetorfuturediagnosticmarker AT marianafloria arterialhypertensionandinterleukinspotentialtherapeutictargetorfuturediagnosticmarker |